Pfizer Hits 11-Year Low And Lingers Sideways For Months — Is It Now A Sell?
Pfizer[ticker symb=PFE] stock continues trending sideways after announcing promising updates for two cancer drugs, but also shutting down a gene therapy program. In one study, multiple myeloma patients who received Pfizer's Elrexfio lived for 24.6 months, at the median. Another study tested Adcetris against chemotherapy in patients with a form of lymphoma.